IN2014DN02014A - - Google Patents

Download PDF

Info

Publication number
IN2014DN02014A
IN2014DN02014A IN2014DEN2014A IN2014DN02014A IN 2014DN02014 A IN2014DN02014 A IN 2014DN02014A IN 2014DEN2014 A IN2014DEN2014 A IN 2014DEN2014A IN 2014DN02014 A IN2014DN02014 A IN 2014DN02014A
Authority
IN
India
Prior art keywords
compound
pregnan
ethynyl
diol
pharmaceutically acceptable
Prior art date
Application number
Other languages
English (en)
Inventor
Backstrom Torbjorn
Ragagnin Gianna
Original Assignee
Umecrine Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umecrine Ab filed Critical Umecrine Ab
Publication of IN2014DN02014A publication Critical patent/IN2014DN02014A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0016—Oximes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IN2014DEN2014 2006-11-21 2007-11-20 IN2014DN02014A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86065806P 2006-11-21 2006-11-21
PCT/SE2007/050876 WO2008063128A1 (en) 2006-11-21 2007-11-20 The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
IN2014DN02014A true IN2014DN02014A (de) 2015-07-10

Family

ID=39429970

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2014DEN2014 IN2014DN02014A (de) 2006-11-21 2007-11-20

Country Status (16)

Country Link
US (9) US8580983B2 (de)
EP (4) EP2792681B1 (de)
JP (5) JP5386362B2 (de)
AU (1) AU2007322423C1 (de)
BR (2) BRPI0718945B8 (de)
CA (2) CA2833976C (de)
DK (3) DK2097437T3 (de)
ES (3) ES2607852T3 (de)
HU (3) HUE036410T2 (de)
IN (1) IN2014DN02014A (de)
MX (1) MX2009005335A (de)
PL (3) PL2097437T3 (de)
PT (1) PT2097437E (de)
RU (1) RU2458065C2 (de)
SI (1) SI2097437T1 (de)
WO (1) WO2008063128A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2607852T3 (es) 2006-11-21 2017-04-04 Umecrine Ab El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
ES2566765T3 (es) 2010-01-14 2016-04-15 Asarina Pharma Ab Una composición farmacéutica que contiene 3-beta-hidroxi-5-alfa-pregnan-20-ona con propiedades de almacenamiento y solubilidad mejoradas
US20130203718A1 (en) * 2010-05-07 2013-08-08 Marie-Edith Rafestin-Oblin Progesterone receptor antagonists and uses thereof
US20150158903A1 (en) 2011-09-08 2015-06-11 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
DK2925770T3 (en) * 2012-11-28 2017-04-10 Univ Bordeaux 3- (4'-SUBSTITUTED) -BENZYL-ETHER DERIVATIVES OF PREGNENOLONE
LT2968369T (lt) 2013-03-13 2018-12-27 Sage Therapeutics, Inc. Neuroaktyvūs steroidai ir jų panaudojimo būdai
RU2684616C2 (ru) 2014-01-29 2019-04-10 Умекрин Когнишн Аб Стероидное соединение для применения в лечении печеночной энцефалопатии
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
ES2793237T3 (es) * 2014-11-27 2020-11-13 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
TWI748936B (zh) 2015-01-12 2021-12-11 瑞典商優鎂奎認知Ａｂ公司 新穎化合物
RS62220B1 (sr) 2015-07-06 2021-09-30 Sage Therapeutics Inc Oksisteroli i postupci njihovog korišćenja
MX376833B (es) 2015-07-06 2025-03-07 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos.
DE102015120587A1 (de) 2015-11-26 2017-06-01 Brandenburgische Technische Universität Cottbus-Senftenberg Verfahren zur selektiven Oxygenierung von Testosteron und Testosteron-ähnlichen Steroiden
CN114272249A (zh) 2016-04-01 2022-04-05 萨奇治疗股份有限公司 氧甾醇及其使用方法
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
ES2952106T3 (es) 2016-10-18 2023-10-27 Sage Therapeutics Inc Oxisteroles y procedimientos de utilización de los mismos
KR20250054838A (ko) 2016-10-18 2025-04-23 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
EP3579842A4 (de) 2017-02-10 2020-12-23 Asarina Pharma AB 3-beta-hydroxy-5-alpha-pregnan-20-on zur verwendung bei der behandlung von essentiellem tremor
CN110430883A (zh) 2017-02-10 2019-11-08 阿沙里那制药公司 用于医学治疗的3β-羟基-5α-孕烷-20-酮
BR112020010519A2 (pt) 2017-11-27 2020-10-20 Umecrine Cognition Ab formulação farmacêutica de oxima de 3¿lfa-etinil-3¿eta-hidroxiandrostan-17-ona
JP2021519799A (ja) 2018-04-05 2021-08-12 アサリナ ファーマ エーピーエス 物質離脱障害を治療するためのｇａｂａ−ａアンタゴニスト
KR102821994B1 (ko) 2019-01-08 2025-06-19 쳉두 캉홍 파마슈티칼 코., 엘티디. 스테로이드 화합물, 및 이의 용도와 제조방법
CN112457362B (zh) * 2019-09-06 2023-09-19 上海青东生物科技有限公司 一种卤代四环三萜衍生物及其制备与应用
EP4079307A1 (de) 2021-04-20 2022-10-26 Umecrine Cognition AB Neue medizinische verwendung
US20240383941A1 (en) 2021-11-10 2024-11-21 Umecrine Ab 3-alpha substituted 3-beta-hydroxy-17-oximated androstane compound for modulation of the alpha-3 subtype of the gabaa receptor
EP4429669A1 (de) 2021-11-10 2024-09-18 Umecrine AB Steroide als modulator des gabaa-rezeptors
EP4430056A1 (de) 2021-11-10 2024-09-18 Umecrine AB 3.beta-hydroxy, 3.alpha-ethylsteroide zur modulation des alpha-3-subtyps des gaba-a-rezeptors
EP4389129A1 (de) * 2022-12-22 2024-06-26 Umecrine Cognition AB 3a-ethinyl-3beta hydroxyandrostan 17-onoxim zur behandlung der parkinsonschen krankheit und l-dopa-induzierte dyskinesie
WO2025252725A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone
WO2025252724A1 (en) 2024-06-04 2025-12-11 Umecrine Cognition Ab Novel pharmaceutical formulation of golexanolone

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463755A (fr) 1960-01-26 1966-07-22 Nouveaux stéroïdes de la série de l'androstane et leur procédé de préparation
US3152121A (en) * 1962-03-16 1964-10-06 Upjohn Co 20-ketals of 3-hydroxy-5 beta-pregnan-20-one
CH491889A (de) * 1966-10-22 1970-06-15 Richter Gedeon Vegyeszet Verfahren zur Herstellung von Steroiden
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5234603A (en) 1991-06-04 1993-08-10 Analytical Development Corporation Methods employing a zirconium salt for use in wastewater treatment
AU698834B2 (en) * 1993-05-24 1998-11-12 Purdue Pharma Ltd. Methods and compositions for inducing sleep
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
NZ282939A (en) * 1994-02-14 1998-08-26 Cocensys Inc Androstanes and pregnanes for allosteric modulation of gaba receptors
WO1996016076A1 (en) * 1994-11-23 1996-05-30 Cocensys, Inc. Androstane and pregnane series for allosteric modulation of gaba receptor
KR19990022323A (ko) * 1995-06-06 1999-03-25 씨. 랜 낸시 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
CA2321728C (en) 1998-03-11 2008-12-09 Torbjorn Backstrom Epiallopregnanolone in the treatment of cns disorders
AU3467699A (en) * 1998-04-14 1999-11-01 Pharmadigm, Inc. Method for reducing central nervous system impairment
US20030060425A1 (en) * 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
CZ294278B6 (cs) * 1999-11-25 2004-11-10 Ústav organické chemie a biochemie AV ČR Neuroaktivní steroidy a způsob jejich přípravy
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
FR2831441B1 (fr) * 2001-10-25 2003-12-26 Oreal Utilisation cosmetique de derives de la dhea
EP1310258A1 (de) 2001-11-08 2003-05-14 Etienne-Emile Baulieu Steroid-Enantiomere zur Erhöhung des Erinnerungsvermögens und der kognitiven Funktion
SE0104423D0 (sv) 2001-12-27 2001-12-27 Umecrine Ab Pregnane steroids and their use in the treatment of CNS disorders
WO2006054938A1 (en) * 2004-11-18 2006-05-26 Umecrine Ab Gaba-steroid antagonists and their use for the treatment of cns disorders
ES2607852T3 (es) * 2006-11-21 2017-04-04 Umecrine Ab El uso de esteroides de pregnano y androstano para la fabricación de una composición farmacéutica para el tratamiento de trastornos del SNC
US20130203718A1 (en) 2010-05-07 2013-08-08 Marie-Edith Rafestin-Oblin Progesterone receptor antagonists and uses thereof

Also Published As

Publication number Publication date
US20140011793A1 (en) 2014-01-09
CA2664126C (en) 2014-04-29
BRPI0718945B8 (pt) 2021-05-25
DK2711371T3 (en) 2018-04-16
US20140011792A1 (en) 2014-01-09
CA2664126A1 (en) 2008-05-29
US9200028B2 (en) 2015-12-01
CA2833976C (en) 2016-03-15
JP2013173782A (ja) 2013-09-05
ES2607852T3 (es) 2017-04-04
RU2458065C2 (ru) 2012-08-10
AU2007322423A1 (en) 2008-05-29
US20080119416A1 (en) 2008-05-22
BRPI0718945A8 (pt) 2017-09-19
US8853190B2 (en) 2014-10-07
PL2792681T3 (pl) 2017-06-30
JP2013177411A (ja) 2013-09-09
BR122013033954B8 (pt) 2021-05-25
AU2007322423C1 (en) 2013-08-15
US20140011779A1 (en) 2014-01-09
AU2007322423B2 (en) 2013-01-10
BRPI0718945A2 (pt) 2013-12-24
US20150315231A1 (en) 2015-11-05
EP2097437B1 (de) 2015-05-27
PT2097437E (pt) 2015-09-15
EP2711371B1 (de) 2018-01-10
HUE033037T2 (hu) 2017-11-28
JP5657052B2 (ja) 2015-01-21
BR122013033954B1 (pt) 2021-01-12
BRPI0718945B1 (pt) 2020-10-13
US8580983B2 (en) 2013-11-12
EP2792681B1 (de) 2016-10-19
US20130102579A1 (en) 2013-04-25
PL2711371T3 (pl) 2018-06-29
US20130102578A1 (en) 2013-04-25
US20130281421A1 (en) 2013-10-24
RU2009107537A (ru) 2010-12-27
MX2009005335A (es) 2009-06-08
DK2792681T3 (en) 2017-01-23
PL2097437T3 (pl) 2015-12-31
EP2792681A1 (de) 2014-10-22
ES2662500T3 (es) 2018-04-06
JP5386362B2 (ja) 2014-01-15
EP2711372A1 (de) 2014-03-26
US20160272670A1 (en) 2016-09-22
JP5918170B2 (ja) 2016-05-18
JP2013173781A (ja) 2013-09-05
EP2097437A1 (de) 2009-09-09
JP2010510210A (ja) 2010-04-02
DK2097437T3 (en) 2015-06-29
ES2543841T3 (es) 2015-08-24
HUE036410T2 (hu) 2018-07-30
EP2711371A1 (de) 2014-03-26
HUE026961T2 (en) 2016-07-28
SI2097437T1 (sl) 2015-10-30
CA2833976A1 (en) 2008-05-29
JP2015147774A (ja) 2015-08-20
EP2097437A4 (de) 2012-12-26
WO2008063128A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
IN2014DN02014A (de)
AP2402A (en) Amine derivatives.
AP2369A (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors.
AP2193A (en) Control system for a pump.
NL300703I2 (nl) Simeprevir, of een farmaceutisch aanvaardbaar zout daarvan, waaronder simeprevirnatrium.
SG143245A1 (en) Channel calibration for a time division duplexed communication system
LU92761I2 (en) N-(5-hydroxy-2,4-diert-butyl-phenyl)-4oxo-1h-quinoline-3-carboxamide or a pharmaceutically acceptable salt thereof
EA200801959A1 (ru) Высокоразветвленный полипропилен
IN2012DN02610A (de)
TNSN08191A1 (en) Kinase inhibitors
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
AP2339A (en) Herbicidal agents.
GB2436104B (en) Vacuum valve for an I.S. machine
WO2009055289A3 (en) Therapeutic substituted lactams
WO2007148102A3 (en) Crystalline duloxetine hydrochloride
EP1835059A4 (de) Schlosssystem
WO2007134168A3 (en) Process for preparing duloxetine
WO2008014084A3 (en) Pipeline
MX2009006745A (es) Macrociclos de amino-tiazol, su uso como compuestos anti-bacterianos y procesos para su produccion.
AP2337A (en) Motilide compounds.
TW200621756A (en) Method for manufacturing enantiomeric imidazole compounds
TW200618799A (en) Method for manufacturing imidazole compounds and salts and pseudopolymorphs thereof
GB2431925B (en) Pushout mechanism for I.S. machine
FR2910232B1 (fr) Machine pour la fenaison, notamment andaineuse.
EP1889636A4 (de) V.a. pervak antireflexiver endotrachealtubus